TY - JOUR
T1 - US-localized diffuse optical tomography in breast cancer
T2 - Comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers
AU - Kim, Min Jung
AU - Su, Min Ying
AU - Yu, Hon J.
AU - Chen, Jeon Hor
AU - Kim, Eun Kyung
AU - Moon, Hee Jung
AU - Choi, Ji Soo
N1 - Publisher Copyright:
© 2016 Kim et al.
Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Background: To correlate parameters of Ultrasonography-guided Diffuse optical tomography (US-DOT) with pharmacokinetic features of Dynamic contrast-enhanced (DCE)-MRI and pathologic markers of breast cancer. Methods: Our institutional review board approved this retrospective study and waived the requirement for informed consent. Thirty seven breast cancer patients received US-DOT and DCE-MRI with less than two weeks in between imaging sessions. The maximal total hemoglobin concentration (THC) measured by US-DOT was correlated with DCE-MRI pharmacokinetic parameters, which included K trans , k ep and signal enhancement ratio (SER). These imaging parameters were also correlated with the pathologic biomarkers of breast cancer. Results: The parameters THC and SER showed marginal positive correlation (r = 0.303, p = 0.058). Tumors with high histological grade, negative ER, and higher Ki-67 expression ≥20 % showed statistically higher THC values compared to their counterparts (p = 0.019, 0.041, and 0.023 respectively). Triple-negative (TN) breast cancers showed statistically higher K trans values than non-TN cancers (p = 0.048). Conclusion: THC obtained from US-DOT and K trans obtained from DCE-MRI were associated with biomarkers indicative of a higher aggressiveness in breast cancer. Although US-DOT and DCE-MRI both measured the vascular properties of breast cancer, parameters from the two imaging modalities showed a weak association presumably due to their different contrast mechanisms and depth sensitivities.
AB - Background: To correlate parameters of Ultrasonography-guided Diffuse optical tomography (US-DOT) with pharmacokinetic features of Dynamic contrast-enhanced (DCE)-MRI and pathologic markers of breast cancer. Methods: Our institutional review board approved this retrospective study and waived the requirement for informed consent. Thirty seven breast cancer patients received US-DOT and DCE-MRI with less than two weeks in between imaging sessions. The maximal total hemoglobin concentration (THC) measured by US-DOT was correlated with DCE-MRI pharmacokinetic parameters, which included K trans , k ep and signal enhancement ratio (SER). These imaging parameters were also correlated with the pathologic biomarkers of breast cancer. Results: The parameters THC and SER showed marginal positive correlation (r = 0.303, p = 0.058). Tumors with high histological grade, negative ER, and higher Ki-67 expression ≥20 % showed statistically higher THC values compared to their counterparts (p = 0.019, 0.041, and 0.023 respectively). Triple-negative (TN) breast cancers showed statistically higher K trans values than non-TN cancers (p = 0.048). Conclusion: THC obtained from US-DOT and K trans obtained from DCE-MRI were associated with biomarkers indicative of a higher aggressiveness in breast cancer. Although US-DOT and DCE-MRI both measured the vascular properties of breast cancer, parameters from the two imaging modalities showed a weak association presumably due to their different contrast mechanisms and depth sensitivities.
UR - http://www.scopus.com/inward/record.url?scp=84957970429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957970429&partnerID=8YFLogxK
U2 - 10.1186/s12885-016-2086-7
DO - 10.1186/s12885-016-2086-7
M3 - Article
C2 - 26833069
AN - SCOPUS:84957970429
VL - 16
JO - BMC Cancer
JF - BMC Cancer
SN - 1471-2407
IS - 1
M1 - 50
ER -